Clinical Research in Asia Shifting Focus to New Emerging Markets
While India and China Are the Traditional Heavyweights, Other Countries Are Now Establishing Better Local Expertise and Regulatory Clarity
(firmenpresse) - RESEARCH TRIANGLE PARK, NC -- (Marketwire) -- 07/19/11 -- Clinical development teams increasingly consider a new group of smaller Asian nations instead of defaulting to established markets, such as India and China, to host sites for , according to a new study by pharmaceutical consulting firm Cutting Edge Information.
The research details clinical development trends and data from China and India as well as trials in Malaysia, Hong Kong, Taiwan, Thailand, Singapore, South Korea and the Philippines. The study, "Emerging Markets Clinical Trials: Asia," examines strategies and best practices for addressing intellectual property concerns and benefiting from strong patient-physician relationships in these emerging markets.
Executives familiar with running previously looked to India and China because of their prominence as the largest two members of the so-called 'BRICs.' Now many see the potential benefits of other Asian countries for clinical development due to each market's unique qualities.
"India and China opened the door for pharma companies to consider focusing on Asia for large parts of their clinical development strategy," said Adam Bianchi, chief operating officer at Cutting Edge Information. "Now we see a more sophisticated breakdown of country-by-country benefits and costs. Many of our benchmark partners are champions within their companies for this change of perspective."
For example, a large company profiled in the study has seen clear advantages to running trials in the Philippines. One of the company's investigational compounds received approval for a new indication supported by clinical data with 30 percent of trial patients enrolled in the Philippines. The Philippines has a relatively long history and the company found that the country's regulatory environment and medical infrastructure offer a solid base for clinical research.
"Emerging Markets Clinical Trials: Asia" provides detailed benchmarking metrics on , including:
Patient access
Patient retention
Regulatory environment
Intellectual property laws/practices
Cultural concerns
Communication and language
Clinical trial technology infrastructure
Supply chain management
Investigators' available knowledge base
Data standards
Investigator standards
Site management standards
Anticipated costs
For more information about managing clinical trials in Asia, or to obtain an excerpt from "Emerging Markets Clinical Trials: Asia," visit or call 919-403-6583.
CONTACT:
Elio Evangelista
+1 919-403-6583
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 19.07.2011 - 13:08 Uhr
Sprache: Deutsch
News-ID 35839
Anzahl Zeichen: 0
contact information:
Town:
RESEARCH TRIANGLE PARK, NC
Kategorie:
Healthcare
Diese Pressemitteilung wurde bisher 321 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Clinical Research in Asia Shifting Focus to New Emerging Markets"
steht unter der journalistisch-redaktionellen Verantwortung von
Cutting Edge Information (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
